These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21094057)

  • 1. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.
    de Denus S; Zakrzewski M; Barhdadi A; Leblanc MH; Racine N; Bélanger F; Carrier M; Ducharme A; Dubé MP; Turgeon J; White M
    J Heart Lung Transplant; 2011 Mar; 30(3):326-31. PubMed ID: 21094057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C; Lerut E; Naesens M; Kuypers DR
    Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
    Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
    Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation.
    Klauke B; Wirth A; Zittermann A; Bohms B; Tenderich G; Körfer R; Milting H
    J Heart Lung Transplant; 2008 Jul; 27(7):741-5. PubMed ID: 18582803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.
    Joy MS; Hogan SL; Thompson BD; Finn WF; Nickeleit V
    Nephrol Dial Transplant; 2007 Jul; 22(7):1963-8. PubMed ID: 17395652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.
    Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
    Clin Ther; 2010 Nov; 32(12):2012-23. PubMed ID: 21118736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation.
    De Meyer M; Haufroid V; Elens L; Fusaro F; Patrono D; De Pauw L; Kanaan N; Goffin E; Mourad M
    J Surg Res; 2012 Dec; 178(2):988-95. PubMed ID: 22835948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
    Yanagimachi M; Naruto T; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto H; Yagihashi T; Kosaki K; Yokota S
    Clin Transplant; 2010; 24(6):855-61. PubMed ID: 20030680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
    Min SI; Kim SY; Ahn SH; Min SK; Kim SH; Kim YS; Moon KC; Oh JM; Kim SJ; Ha J
    Transplantation; 2010 Dec; 90(12):1394-400. PubMed ID: 21076384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.
    Torio A; Auyanet I; Montes-Ares O; Guerra RM; Fernandez EJ; Perez MA; Ramirez A; Checa MD
    Transplant Proc; 2012 Nov; 44(9):2596-8. PubMed ID: 23146466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I; Hsaiky L; Brown K; Abouljoud M
    Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.